{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:51:13Z","timestamp":1790254273571,"version":"4.1.0"},"reference-count":74,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Womens Health (Lond Engl)"],"published-print":{"date-parts":[[2014,1]]},"abstract":"<jats:p> The purpose of this review is to describe the available evidence for osteoporosis treatments in young and premenopausal women. A review of articles evaluating the treatment or prevention of osteoporosis in young (age less than 50 years) or premenopausal women was conducted. Several trials evaluating the treatment of anorexia nervosa and use of hormone therapy in those women, the use of bisphosphonates in women undergoing chemotherapy for breast cancer and the use of bisphosphonates, teriparatide and vitamin D in women with glucocorticoid-induced osteoporosis are described. Limited data were found to support the treatment of osteoporosis in women with idiopathic osteoporosis or cystic fibrosis, or after kidney transplant. The evidence for treatment of osteoporosis in premenopausal women is not nearly as robust as that for postmenopausal osteoporosis. Although fracture risk in the premenopausal population is low, women with secondary osteoporosis may benefit from treatment with various agents, depending upon the condition. <\/jats:p>","DOI":"10.2217\/whe.13.73","type":"journal-article","created":{"date-parts":[[2013,12,11]],"date-time":"2013-12-11T14:10:26Z","timestamp":1386771026000},"page":"59-77","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":17,"title":["A Review of Osteoporosis Management in Younger Premenopausal Women"],"prefix":"10.1177","volume":"10","author":[{"given":"Amber N","family":"McLendon","sequence":"first","affiliation":[{"name":"Campbell University College of Pharmacy & Health Sciences & Glenaire, Inc., PO Box 1090, Buies Creek, NC 27511, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C Brock","family":"Woodis","sequence":"additional","affiliation":[{"name":"Campbell University College of Pharmacy & Health Sciences & Duke Family Medicine, PO Box 1090, Buies Creek, NC 27511, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2014,1,1]]},"reference":[{"key":"bibr1a-WHE.13.73","unstructured":"Papers of special note have been highlighted as:"},{"key":"bibr2a-WHE.13.73","unstructured":"of interest"},{"key":"bibr3a-WHE.13.73","unstructured":"of considerable interest"},{"issue":"2","key":"bibr1-WHE.13.73","first-page":"93","volume":"8","author":"Martinez-Morillo M","year":"2012","journal-title":"Rheumatol. Clin."},{"key":"bibr2-WHE.13.73","volume-title":"Osteoporosis: Peak Bone Mass in Women.","author":"NIH Osteoporosis and Related Bone Diseases National Resource Center","year":"2012"},{"key":"bibr3-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1592\/phco.29.3.305"},{"key":"bibr4-WHE.13.73","volume-title":"Clinician's Guide to the Prevention and Treatment of Osteoporosis.","author":"National Osteoporosis Foundation","year":"2013"},{"key":"bibr5-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-009-0917-y"},{"key":"bibr9a-WHE.13.73","unstructured":"Demonstrates the value of osteoporosis treatment for glucocorticoid-induced osteoporosis (GIO) and compares the results in premenopausal with postemenopausal women. The results are also broken down by age and provide insight into management for women under 35 years of age."},{"key":"bibr6-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwf049"},{"key":"bibr7-WHE.13.73","volume-title":"What Women Need to Know.","author":"National Osteoporosis Foundation","year":"2013"},{"key":"bibr8-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2010.01.006"},{"key":"bibr9-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.78a.10023"},{"key":"bibr10-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1089\/jwh.2008.0887"},{"key":"bibr11-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-0124"},{"key":"bibr16a-WHE.13.73","unstructured":"The diagnostic criteria for premenopausal osteoporosis are contained in these guidelines. The need for additional fracture risks beyond low Z-scores is also discussed."},{"key":"bibr12-WHE.13.73","doi-asserted-by":"crossref","unstructured":"Uusi-Rasi K, Karkkainen MU, Lamberg-Allardt CJ. Calcium intake in health maintenance \u2013 a systematic review. Food Nutr. Res. doi:10.3402\/fnr.v57i0.21082 (2013) (Epub ahead of print).","DOI":"10.3402\/fnr.v57i0.21082"},{"key":"bibr13-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-006-0405-0"},{"key":"bibr19a-WHE.13.73","unstructured":"Only study that exclusively evaluates osteoporosis treatment in those with idiopathic osteoporosis. Also the only study to examine the benefits of calcium\/vitamin D alone to treat osteoporosis."},{"key":"bibr14-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1089\/154099904323016455"},{"key":"bibr15-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1007\/s007740170051"},{"key":"bibr16-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2000.15.12.2495"},{"issue":"4","key":"bibr17-WHE.13.73","first-page":"246","volume":"37","author":"Dornerman TM","year":"1997","journal-title":"J. Sports Med. Phys. Fitness"},{"key":"bibr18-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-008-0554-3"},{"key":"bibr19-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.4158\/EP.16.S3.1"},{"key":"bibr20-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.2174\/157488610790936178"},{"key":"bibr21-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2548"},{"issue":"8","key":"bibr22-WHE.13.73","first-page":"1023","volume":"165","author":"Prior JC","year":"2001","journal-title":"CMAJ"},{"key":"bibr23-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20295"},{"key":"bibr30a-WHE.13.73","unstructured":"These recommendations are the most up-to-date information on management of GIO. Algorithms for treatment in premenopausal women are included."},{"issue":"3","key":"bibr24-WHE.13.73","first-page":"239","volume":"56","author":"Law R","year":"2010","journal-title":"Can. Fam. Physician"},{"key":"bibr25-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-008-9173-y"},{"key":"bibr26-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2818"},{"key":"bibr27-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1460045"},{"key":"bibr28-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1016\/S1083-3188(02)00145-6"},{"issue":"3","key":"bibr29-WHE.13.73","first-page":"898","volume":"80","author":"Klibanski A","year":"1995","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"bibr30-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadohealth.2006.09.010"},{"key":"bibr31-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-007-0439-4"},{"key":"bibr32-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4707"},{"key":"bibr33-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-10-200605160-00009"},{"key":"bibr34-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.08.017"},{"key":"bibr42a-WHE.13.73","unstructured":"Reviews the benefits of bisphosphonates in women undergoing chemotherapy for breast cancer. Risks of treatment in younger women are also discussed."},{"key":"bibr35-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-010-1201-8"},{"key":"bibr36-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.7102"},{"key":"bibr37-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70204-3"},{"key":"bibr38-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-1366"},{"key":"bibr39-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.1783"},{"key":"bibr40-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-1272"},{"key":"bibr41-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.2967"},{"key":"bibr42-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.3.955"},{"key":"bibr43-WHE.13.73","volume-title":"prescribing information","author":"FOSAMAX\u00ae","year":"2013"},{"key":"bibr44-WHE.13.73","volume-title":"prescribing information","author":"Actonel\u00ae","year":"2013"},{"key":"bibr45-WHE.13.73","volume-title":"prescribing information","author":"Reclast\u00ae","year":"2013"},{"key":"bibr46-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-012-1958-1"},{"key":"bibr47-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-011-1800-1"},{"key":"bibr48-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60250-6"},{"key":"bibr49-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053569"},{"key":"bibr58a-WHE.13.73","unstructured":"Demonstrates fracture prevention for a bisphosphonate in GIO compared with other active treatments."},{"key":"bibr50-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa071408"},{"key":"bibr51-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1002\/art.24879"},{"key":"bibr52-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/38.12.1239"},{"key":"bibr53-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-0608"},{"key":"bibr54-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200307-1049OC"},{"key":"bibr55-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00816.x"},{"key":"bibr56-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00369.x"},{"key":"bibr57-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V1271530"},{"key":"bibr58-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(94)90092-2"},{"key":"bibr59-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1007\/s001980170079"},{"key":"bibr60-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705196"},{"key":"bibr61-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199412153312404"},{"key":"bibr62-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2000.16518"},{"key":"bibr63-WHE.13.73","doi-asserted-by":"publisher","DOI":"10.1007\/BF02555921"},{"key":"bibr101-WHE.13.73","unstructured":"WHO Fracture Risk Assessment Tool. www.shef.ac.uk\/FRAX"},{"key":"bibr102-WHE.13.73","unstructured":"Jules Bordet Institute. A study to evaluate denosumab in young patients with primary breast cancer (D-BEYOND). www.clinicaltrials.gov\/show\/NCT01864798"}],"container-title":["Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.2217\/WHE.13.73","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.2217\/WHE.13.73","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.2217\/WHE.13.73","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T15:47:25Z","timestamp":1741621645000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.2217\/WHE.13.73"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["10.2217\/WHE.13.73"],"URL":"https:\/\/doi.org\/10.2217\/whe.13.73","relation":{},"ISSN":["1745-5057","1745-5065"],"issn-type":[{"value":"1745-5057","type":"print"},{"value":"1745-5065","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}